Accepted for Publication: August 5, 2021.
Published Online: September 27, 2021. doi:10.1001/jamaneurol.2021.3310
Corresponding Author: Keith Vossel, MD, MSc, Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, 710 Westwood Plaza, RNRC C-224, Los Angeles, CA 90095 (email@example.com).
Author Contributions: Drs Vossel and Ranasinghe had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Vossel, Ranasinghe, Mucke, Possin, Boxer, Miller, Nagarajan, Kirsch.
Acquisition, analysis, or interpretation of data: Vossel, Ranasinghe, Beagle, La, Ah Pook, Castro, Mizuiri, Honma, Venkateswaran, Koestler, Zhang, Mucke, Howell, Possin, Kramer, Boxer, Nagarajan, Kirsch.
Drafting of the manuscript: Vossel, Ranasinghe, La, Ah Pook, Howell, Kramer.
Critical revision of the manuscript for important intellectual content: Vossel, Ranasinghe, Beagle, Castro, Mizuiri, Honma, Venkateswaran, Koestler, Zhang, Mucke, Possin, Boxer, Miller, Nagarajan, Kirsch.
Statistical analysis: Vossel, Ranasinghe, Venkateswaran, Mucke, Possin, Nagarajan.
Obtained funding: Vossel, Mucke.
Administrative, technical, or material support: Vossel, Beagle, La, Castro, Mizuiri, Honma, Venkateswaran, Koestler, Zhang, Howell, Boxer, Miller, Nagarajan.
Supervision: Vossel, Ranasinghe, Boxer, Miller, Nagarajan.
Conflict of Interest Disclosures: Dr Vossel reported receiving grants from the Alzheimer’s Association and the National Institute on Aging, National Institutes of Health and donations from the Fineberg Foundation, the N. Bud and Beverly Grossman Foundation, and the S. D. Bechtel, Jr. Foundation during the conduct of the study. Dr Mucke reported receiving grants from the S. D. Bechtel, Jr. Foundation during the conduct of the study and research funding for an independent project from Cure Network Dolby Acceleration Partners; personal fees from Eisai and Takeda Pharmaceutical; and serving on the scientific advisory boards of Acumen, Alkahest, Arvinas, Biogen, and Dolby Family Ventures outside the submitted work. Dr Possin reported receiving grants from the Global Brain Health Institute, the National Institutes of Health, the Rainwater Charitable Foundation, and Quest Diagnostics during the conduct of the study and personal fees from ClearView Healthcare Partners and Vanguard outside the submitted work. Dr Boxer reported receiving grants from the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, the Association for Frontotemporal Degeneration, Biogen, the Bluefield Project to Cure Frontotemporal Dementia, Eisai, Eli Lilly and Company, the National Institutes of Health, the Rainwater Charitable Foundation, Regeneron Pharmaceuticals, and the State of California; personal fees from Alector, Applied Genetic Technologies, Arkuda Therapeutics, Arvinas, AZTherapies, GlaxoSmithKline, Humana, Lundbeck, Oligomerix, Roche, the Roissy Foundation, Stealth BioTherapeutics, Transposon Therapeutics, TrueBinding, UCB, and Wave Pharma; and nonfinancial support from Eli Lilly and Company and Novartis; and serving as a consultant for Applied Genetic Technologies, Alector, Arkuda Therapeutics, Arvinas, Asceneuron, AZTherapies, BioAge Labs, GlaxoSmithKline, Humana, Oligomerix, Ono Pharmaceutical, Roche, Samumed, Sangamo Therapeutics, Stealth BioTherapeutics, Third Rock Ventures, Transposon Therapeutics, and Wave Pharma outside the submitted work. Dr Miller reported receiving grants from the Bluefield Project to Cure Frontotemporal Dementia and royalties from the Cambridge University Press, Guilford Press, John Hopkins Press, and Oxford University Press; being the editor-in-chief of Neurocase and a section editor of Frontiers in Neurology; serving as a scientific advisor, consultant, or board member for the Bluefield Project to Cure Frontotemporal Dementia, Biogen, the Buck Institute for Research on Aging, the National Institute for Health Research Cambridge Biomedical Research Centre and its Biomedical Research Unit in Dementia, the John Douglas French Alzheimer’s Foundation, the Larry L. Hillblom Foundation, the Massachusetts General Hospital/Harvard Medical School Alzheimer’s Disease Research Center, the Rainwater Charitable Foundation, SafelyYou, the Stanford Alzheimer’s Disease Research Center, The University of Texas at Dallas Center for BrainHealth, and the University of Washington Alzheimer’s Disease Research Center outside the submitted work. Dr Nagarajan reported receiving grants from RICOH MEG outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by grant PCTRB-13-288476 from the Alzheimer’s Association made possible by Part the Cloud (Dr Vossel); grants K23 AG038357 (Dr Vossel), K08 AG058749 (Dr Ranasinghe), F32 AG050434 (Dr Ranasinghe), R01 NS100440 (Dr Nagarajan), RF1 AG062196 (Dr Nagarajan), R01 DC017696 (Dr Nagarajan), P50 AG023501 (Dr Miller), and P01 AG19724 (Dr Miller) from the National Institutes of Health; grant 2015-A-034-FEL from the Larry L. Hillblom Foundation (Dr Ranasinghe), and funding from the Fineberg Foundation (Dr Vossel), the N. Bud and Beverly Grossman Foundation (Dr Vossel), and the S. D. Bechtel, Jr. Foundation (Drs Vossel and Mucke).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the participants and study partners for their generous time and commitment to this study. Marcos Contreras, PharmD, of the University of California, San Francisco, Drug Product Services Laboratory, and Karen Muir, RPh, of Safeway Compounding Pharmacy created and maintained the blinded randomization scheme. Deborah Barnes, PhD, of the University of California, San Francisco, provided advice on study design. Kirsten Peterson, RPSGT, and Amy Pearson, RPSGT, of the University of Minnesota provided technical assistance with sleep and electroencephalography studies. Sarah Ellis, CCRC, and Deanna Dickens, MD, of United Hospital assisted with setting up the magnetoencephalography plus electroencephalography research studies. Robert Rissman, PhD, of the University of California, San Diego, performed cerebrospinal fluid analysis on 3 samples. Melissa Terpstra, PhD, of the University of Minnesota assisted with setting up the magnetic resonance imaging research protocol. Zuzan Cayci, MD, of the University of Minnesota read the results of amyloid positron emission tomography for 1 participant. None of these individuals received financial compensation for their contributions.
A , Szucs
A , Hidasi
Z , Csukly
G , Barcs
G , Kamondi
A . Prevalence, semiology, and risk factors of epilepsy in Alzheimer’s disease: an ambulatory EEG study. J Alzheimers Dis
. 2018;63(3):1045-1054. doi:10.3233/JAD-170925
PE , Zhu
L , Verret
et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci U S A
. 2012;109(42):E2895-E2903. doi:10.1073/pnas.1121081109
JQ , Wang
BR , Tian
et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther
. 2013;19(11):871-881. doi:10.1111/cns.12144
CH , Iascone
DM , Petrof
et al. Early seizure activity accelerates depletion of hippocampal neural stem cells and impairs spatial discrimination in an Alzheimer’s disease model. Cell Rep
. 2019;27(13):3741-3751. doi:10.1016/j.celrep.2019.05.101
AD , Deck
G , Goldman
A , Eskandar
EN , Noebels
J , Cole
AJ . Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer’s disease. Nat Med
. 2017;23(6):678-680. doi:10.1038/nm.4330
GM , Knopman
DS , Chertkow
et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement
. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005
MP , Ayre
GA , Cummings
et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry
. 2000;177:252-256. doi:10.1192/bjp.177.3.252
LS , Olin
JT , Doody
et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study–Clinical Global Impression of Change. the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord
. 1997;11(suppl 2):S22-S32. doi:10.1097/00002093-199700112-00004
JL , Mega
M , Gray
K , Rosenberg-Thompson
S , Carusi
DA , Gornbein
J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology
. 1994;44(12):2308-2314. doi:10.1212/WNL.44.12.2308
J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.
M , Stam
CJ , van der Flier
WM , Pijnenburg
YAL , Scheltens
P . Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord
. 2010;29(5):432-437. doi:10.1159/000278620
S , Dolatabadi
N , Trudler
et al. Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. Elife
. 2019;8:e50333. doi:10.7554/eLife.50333
B , Simon
MM , Hong
et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science
. 2019;365(6453):559-565. doi:10.1126/science.aay0198
A , Albert
MS , Krauss
G , Speck
CL , Gallagher
M . Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin
. 2015;7:688-698. doi:10.1016/j.nicl.2015.02.009
AJ , Darwish
SM , Ranasinghe
KG , La
AL , Karageorgiou
E , Vossel
KA . Relative incidence of seizures and myoclonus in Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis
. 2017;60(1):211-223. doi:10.3233/JAD-170031
KG , Cha
J , Iaccarino
et al. Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline. Sci Transl Med
. 2020;12(534):eaaz4069. doi:10.1126/scitranslmed.aaz4069